mRNA Synthesis and Manufacturing Market size worth close to USD 0.58 billion by 2035 | Roots Analysis
The mRNA Synthesis and Manufacturing Market is anticipated to be worth USD 1.06 billion in 2024, and this value is likely to be USD 0.58 billion in 2035.
Messenger ribonucleic acid (mRNA) has become an important part of modern healthcare, having various advantages including rapid development cycle, enhanced safety and scalability. It is worth mentioning that the first mRNA vaccines (namely COMIRNATY and Spikevax) were developed amidst the COVID-19 pandemic, marking a significant milestone in the field of vaccine development.
Further, the ongoing research has expanded the therapeutic applications of mRNA beyond infectious diseases, to autoimmune disorders, genetic disorders and cancer. However, the mRNA synthesis and manufacturing process is fraught with concerns related to stability, purity, quality and regulatory. Therefore, various companies are increasingly relying on contract manufacturers for their support in the production of mRNA / mRNA-based drugs.
According to Roots Analysis, the mRNA Synthesis and Manufacturing Market is anticipated to be worth USD 1.06 billion in 2024, and this value is likely to be USD 0.58 billion in 2035.
Key Report Takeaways
Presently, over 35 mRNA custom synthesis service providers are available globally; further, most of the players offer mRNA purification services (specifically chromatography and electrophoresis)
More than 40 firms currently claim to offer contract manufacturing services for mRNA as well as mRNA-based products (vaccines and therapeutics); majority of the companies are very large players
Over 95 kits are available in the market for the customized synthesis of mRNA; notably, most of these kits comprise of capping enzymes
To achieve a competitive edge over their competitors, various firms are actively undertaking initiatives to enhance their service as well as product portfolios
Over 70 deals have been forged related to mRNA (since 2019) by various stakeholders; in addition, most of the partnerships were manufacturing agreements
Various big pharma players have undertaken a myriad of initiatives (including collaborations, acquisitions, funding and expansion) for advancing their mRNA-related portfolio and therapeutic applicability
The mRNA synthesis and manufacturing market is anticipated to be driven by the ongoing technological advancements, growing demand for mRNA vaccines (for different indications) and development of innovative mRNA-based therapeutics
Competitive Landscape:
The current market landscape features a mix of over 40 very large, large, mid-sized and small companies, which claim to have the required expertise to offer various services for the contract manufacturing of mRNAs. Around 50% of the players claim to offer contract services for both drug substance (mRNA) and drug product (mRNA-based vaccines and therapeutics).
Competitive Landscape of mRNA Synthesis Kits
The current market landscape features the presence of over 95 kits that are currently available for the synthesis of mRNA. Close to 50% of mRNA synthesis kits contain all the components (including enzyme mix, buffers and other reagents) required to synthesize mRNA. Further, close to 30% of players involved in the mRNA synthesis kit domain are well-established firms; around 65% of the companies are based in North America, followed by Europe (over 20%).
Regional Outlook
Based on the key geographical regions, mRNA synthesis and manufacturing market can be segmented into four major regions, including North America, Europe, Asia Pacific and Rest of the World. North America is anticipated to capture majority share of the mRNA synthesis and manufacturing market in 2024, and this trend is likely to remain unchanged during the forecast period.
mRNA synthesis and manufacturing market Key Players
Examples of key companies engaged in mRNA synthesis and manufacturing market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Aldevron, APExBIO, Aurigene Pharmaceutical Services, Biomay, CELLSCRIPT, Curia, eTheRNA, Enzynomics, Eurogentec, GenScript, Jena Bioscience, Merck KGaA, New England Biolabs, Vernal Biosciences, ST Pharm, Thermo Fisher Scientific, TriLink BioTechnologies, WuXi Biologics.
It is interesting to note that in November 2023, TriLink BioTechnologies launched its Analytical Sciences Center of Excellence (ASCE) to expand its extensive suite of analytical testing capabilities.
mRNA Synthesis and Manufacturing Market Segments
Based on the research, Roots Analysis has segmented the mRNA synthesis and manufacturing market by Type of Product, Application Area, Therapeutic Area and Key Geographical Regions.
by Type of Product
Drug Substance (APIs)
Drug Product (FDFs)
by Application Area
mRNA-based Vaccines
mRNA-based Therapeutics
by Therapeutic Area
Infectious Diseases
Oncological Disorders
Other Disorders
by Key Geographical Regions
North America
Europe
Asia-Pacific
Rest of the World
About Roots Analysis
Roots Analysis is a global leader in the market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the subject given. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serving our clients in the best possible way.
Contact US
Gaurav Chaudhary
Email: sales@rootsanalysis.com
